ライフサイエンスコーパス: pulmonary function test

1 al interstitial pneumonia than an individual pulmonary function test.

2 r-mo/cc cumulative exposure prior to initial pulmonary function test.

3 rs and accumulated RCF exposure from initial pulmonary function test.

4 -Pick disease was evaluated with imaging and pulmonary function tests.

5 ndings are more sensitive as compared to the pulmonary function tests.

6 who had significantly abnormal pretransplant pulmonary function tests.

7 , echocardiogram, treadmill stress test, and pulmonary function tests.

8 aded exercise testing, echocardiography, and pulmonary function tests.

9 h LAM (17 with pleurodesis) underwent CT and pulmonary function tests.

10 able from traditional imaging modalities and pulmonary function tests.

11 d by symptom activity than medication use or pulmonary function tests.

12 luded in the analysis provided at least five pulmonary function tests.

13 ry symptom questionnaire; 736 also performed pulmonary function tests.

14 s from a 15-item questionnaire and completed pulmonary function tests.

15 ar retinal nerve fiber layer correlates with pulmonary function tests.

16 need for a standardized reporting format for pulmonary function tests.

17 standardized interview, skin prick tests and pulmonary function tests.

18 hickness, and body composition), asthma, and pulmonary function tests.

19 ee survival, modified Rodnan skin score, and pulmonary function tests.

20 ved in kidney angiomyolipoma size but not in pulmonary function tests.

21 nts were prospectively followed with routine pulmonary function tests.

22 ed diffusion capacity for carbon monoxide on pulmonary function testing.

23 ion, and the following day were subjected to pulmonary function testing.

24 in a group of patients who were referred for pulmonary function testing.

25 the patients were correlated with results of pulmonary function testing.

26 A diagnosis of asthma was confirmed by pulmonary function testing.

27 nonobstructive pattern (FEV(1):VC >/=0.7) in pulmonary function tests 3 months after transplantation.

28 sometimes in individuals without symptoms or pulmonary function test abnormalities.

29 The CPI was derived in group I (by fitting pulmonary function tests against disease extent on CT) a

30 included individual arm and leg megascores, pulmonary function tests, an activities-of-daily-living

31 comitant symptoms, the physical examination, pulmonary function testing and arterial blood gas analys

32 th SSc and dyspnea were evaluated for ILD by pulmonary function testing and bronchoalveolar lavage (B

33 pational asbestos exposure who had undergone pulmonary function testing and computed tomographic (CT)

34 nt (HDC/ABMT) for primary breast cancer with pulmonary function testing and computed tomography at re

35 ysis of variance, and the relationships with pulmonary function testing and eosinophil counts were as

36 dditional research about the roles of infant pulmonary function testing and food avoidance or dietary

37 To review the recent literature related to pulmonary function testing and how it relates to the pre

38 CT scores were then compared with results of pulmonary function testing and patient age by means of l

39 univariable and multivariable analyses with pulmonary function testing and quality of life survey da

40 Other pulmonary function tests and arterial blood gas measurem

41 Pulmonary function tests and Brasfield scores were withi

42 ho had undergone pre- and postbronchodilator pulmonary function tests and computed tomographic (CT) e

43 macular sub-layer thickness measurements and pulmonary function tests and disease duration.

44 mographic and clinical parameters, including pulmonary function tests and high resolution computed to

45 Metabolic stress testing (VO(2)), pulmonary function tests and isokinetic strength testing

46 Results of pulmonary function tests and other measures of major org

47 Relationships between findings at CT and pulmonary function tests and the influence of pleurodesi

48 Pulmonary function tests and time since symptom onset we

49 m the diaphragms of two patients with normal pulmonary function tests and two patients with severe CO

50 ictive lung pattern revealed by preoperative pulmonary function tests) and the transfusion (blood uni

51 .5 (range, 21.0-67.8) years at time of first pulmonary function test, and a median follow-up of 5.5 y

52 pneumonia, fixed obstructive lung disease on pulmonary function testing, and characteristic changes o

53 tom scores, arterial blood gas measurements, pulmonary function testing, and chest radiographs.

54 tric measurements, resting echocardiography, pulmonary function tests, and a cardiopulmonary exercise

55 All patients underwent pulmonary function tests, and measurement of fraction of

56 ic resonance imaging (MRI), echocardiograms, pulmonary function tests, and physical examinations.

57 l infiltrates, gas exchange abnormalities on pulmonary function tests, and pleural thickening on ches

58 and exposure history, physical examination, pulmonary-function testing, and high-resolution computed

59 >/=10% decline in FEV1 relative to the prior pulmonary function test, are subsequently at increased r

60 ic fibrosis pulmonary disease is assessed by pulmonary function tests, arterial blood gases, and ches

61 Response was monitored by chest radiographs, pulmonary function tests, arterial blood gases, and grad

62 Measurements: Polysomnography, pulmonary function tests, arterial blood gases, and left

63 ized organisms does not occur during routine pulmonary function testing as long as an interval of 5 m

64 Pulmonary function tests, Asthma Control Test (ACT), Ast

65 rticosteroids, use of inhaled beta-agonists, pulmonary function tests, asthma symptom assessment, and

66 ell Disease, was constructed using the first pulmonary function test at >21 years of age.

67 nts from 12 trial centers were recruited for pulmonary function testing at a single center.

68 Among survivors with normal pulmonary function tests at t1, females and survivors tr

69 ated more strongly (rho = 0.75, P <.01) with pulmonary function test-based scores than did inspirator

70 n by graft bronchoalveolar lavage cells, and pulmonary function testing before and during cyclosporin

71 nt Gal-3 assessment using plasma samples and pulmonary function testing between 1995 and 1998.

72 bjects and 30 patients with asthma underwent pulmonary function tests, blood and sputum eosinophil co

73 ollowed and outcome measures included serial pulmonary function tests, blood gases, lung compliance,

74 We analyzed pulmonary function tests, blood, and bronchoscopic biops

75 Pulmonary function tests, Brasfield scores, arterial blo

76 high-resolution computed tomography, infant pulmonary function testing, bronchoscopy with bronchoalv

77 thy lungs and are related to measurements of pulmonary function testing but not to eosinophil level.

78 ant linear correlations with measurements of pulmonary function testing but not with eosinophil level

79 t clinical improvement with normalization of pulmonary function tests by 1 year posttransplant.

80 Pulmonary function testing can be used to quantify lung

81 , serum ferritin (iron overload, 24.0%), and pulmonary function testing/chest x-ray (pulmonary dysfun

82 Each subject underwent pulmonary function testing, completed a detailed questio

83 tricular tachycardia episodes (p=0.025), and pulmonary function testing demonstrated improved forced

84 extent on CT (r2 = 0.51) than the individual pulmonary function test (DLCO the highest value, r2 = 0.

85 clinical history and examination, CD4 count, pulmonary function tests, Doppler echocardiography, and

86 xamination that included carotid ultrasound, pulmonary function tests, ECG, and echocardiography.

87 ounds should be considered when interpreting pulmonary function tests, especially when predicted valu

88 ubjects underwent sputum and blood analyses, pulmonary function testing, exercise tolerance, and qual

89 .20 +/- 0.17, FEV1/FVC 40 +/- 3) we measured pulmonary function tests, exercise breathlessness by Bor

90 as performed using questionnaires, atopy and pulmonary function testing, exhaled nitric oxide measure

91 administered before and after exposure, and pulmonary function tests (FEV1, FVC, and specific airway

92 administered before and after exposure, and pulmonary function tests (FEV1, FVC, and SRaw) were perf

93 ased inspiratory flows at rest measured with pulmonary function tests (forced inspiratory volume in o

94 ent's global assessment of disease activity, pulmonary function tests (forced vital capacity, diffusi

95 rs examined cross-sectional dietary data and pulmonary function tests from 2,566 children aged 11-19

96 Pulmonary function tests, gas exchange, 6-min walk dista

97 All pulmonary function tests had returned to baseline values

98 Postoperative pulmonary function testing has shown significant improve

99 rocardiograms (EKGs), chest radiographs, and pulmonary function tests have been obtained from each pa

100 ective standardized evaluation included full pulmonary function testing, high-resolution chest tomogr

101 Symptomatic employees had chest radiography, pulmonary function tests, high-resolution computed tomog

102 edicted more accurately by the CPI than by a pulmonary function test in all clinical subgroups, inclu

103 ays directly, but unfortunately conventional pulmonary function tests in human subjects are not speci

104 Pulmonary function tests in infants have been used for m

105 The three methods and the pulmonary function tests in the normal and emphysema gro

106 Baseline pulmonary function tests included spirometry before and

107 Pulmonary function tests, including lung volumes, arteri

108 tion computed tomography (HRCT) patterns and pulmonary function tests, including the composite physio

109 Although pulmonary function test indexes may be abnormal, imaging

110 were evaluated with a symptom questionnaire, pulmonary function testing, intradermal allergen testing

111 t forced expiratory flows and volumes infant pulmonary function tests (iPFTs) were measured in 44 inf

112 An obstructive pattern in pulmonary function test is common after lung transplanta

113 , the quantitation of disease severity using pulmonary function tests is often confounded by emphysem

114 ological and neuropsychological assessments, pulmonary function tests, liver and spleen organ volumes

115 Exertional dyspnea disproportionate to pulmonary function tests, low carbon monoxide diffusion

116 Pulmonary function tests, markers of atopy, asthma diagn

117 Correlations between mean ADC values and pulmonary function test measurements for diagnosing emph

118 and, according to their symptoms, underwent pulmonary function testing, methacholine challenge, spec

119 mes included abnormalities determined by the pulmonary function tests of forced vital capacity (FVC)

120 ing questionnaires or office-based screening pulmonary function testing or to determine the benefits

121 at least 25 percent in exercise tolerance or pulmonary-function tests or resolution or absence of pul

122 f inhaled corticosteroids were predictive of pulmonary function tests' outcome.

123 r than 18 yr of age and performed at least 3 pulmonary function tests over 5 to 20 yr.

124 During an asthma exacerbation, pulmonary function test parameters (PFTs) return to thei

125 Infant pulmonary function testing performed as an exploratory o

126 Study participants had pulmonary function testing performed at regular preset i

127 All patients had normal biopsy and stable pulmonary function test (PFT) results 2-36 weeks prior t

128 ere assessed by using chest radiographic and pulmonary function test (PFT) results in 93 patients.

129 tomography (CT) metrics on a lobar basis and pulmonary function test (PFT) results on a whole-lung ba

130 sing spondylitis (AS) and compared them with pulmonary function test (PFT) results, demographic chara

131 f asthma and/or EIB were required to undergo pulmonary function testing (PFT) to permit the use of in

132 Serial pulmonary function testing (PFT) was performed.

133 Respiratory muscle function was assessed by pulmonary function testing (PFT).

134 We performed pulmonary function tests (PFT), measured slope of phase

135 duration of illness, laboratory results and pulmonary function tests (PFT).

136 Pulmonary function tests (PFTs) and symptom evaluation w

137 Pulmonary function tests (PFTs) are routinely used to as

138 erogeneity is greater in smokers with normal pulmonary function tests (PFTs) but who have visual evid

139 Besides the global pulmonary function tests (PFTs) imaging techniques gaine

140 We sought to perform objective pulmonary function tests (PFTs) in HIV-infected and HEU

141 Pulmonary function tests (PFTs) included forced vital ca

142 Pulmonary function tests (PFTs) that measured the diffus

143 After the stabilization period, pulmonary function tests (PFTs) were measured (period 1)

144 Pulmonary function tests (PFTs) were performed before in

145 d to assess the correlation of CT scores and pulmonary function tests (PFTs) with this clinical outco

146 33 UW and 57 NW patients and compared their pulmonary function tests (PFTs), arterial blood gases (A

147 Unfortunately many of them, for example pulmonary function tests (PFTs), clinical signs and conv

148 ging session followed by clinically standard pulmonary function tests (PFTs), the 6-minute walk test,

149 cluded time to death or worsening results of pulmonary function tests (PFTs).

150 mptom-limited incremental cycle exercise and pulmonary functions tests (PFTs) and were compared with

151 h SA and its specific characteristics (i.e., pulmonary function tests, quality of life scores, urgent

152 After 8 wk of pulmonary rehabilitation, pulmonary function tests remained unchanged compared wit

153 went history, physical examination, complete pulmonary function testing, respiratory muscle testing,

154 Changes reported in analysis of pulmonary function test results and their follow-up migh

155 available in the United States; if baseline pulmonary function test results are normal to near norma

156 Pulmonary function test results before and after ARS rev

157 relation between CT finding extent score and pulmonary function test results was estimated with Spear

158 Age and pulmonary function test results were similar in RA and n

159 ge (BAL) cell components, chest radiography, pulmonary function test results, and exercise physiology

160 A review of clinical records, pulmonary function test results, and findings on imaging

161 On the basis of clinical information and pulmonary function test results, disease in 53 patients

162 Of the 15 control patients with normal pulmonary function test results, six (40%) had mosaic pe

163 malignancy, and had available pretransplant pulmonary function test results.

164 evelop a new Technical Standard on reporting pulmonary function test results.

165 the relationship between CT measurements and pulmonary function test results.

166 True diagnosis was based on pulmonary function test results.

167 f air trapping correlated significantly with pulmonary function test results.

168 have CT abnormalities than those with normal pulmonary function test results.

169 g Final diagnoses in all patients were based pulmonary function test results.

170 est, exercise), PaO2, hemoglobin, or resting pulmonary function test results.

171 c (HLA class II and FBN1 genotypes) factors; pulmonary function test results; electrocardiograms; and

172 Pulmonary function testing revealed no significant diffe

173 Pulmonary function testing revealed severe airflow limit

174 Both pre- and postexercise pulmonary function tests revealed air trapping and mild

175 In addition, pulmonary function tests revealed stable vital capacity

176 Pulmonary function testing reveals an obstructive ventil

177 atients evaluated with standard preoperative pulmonary function tests, RV/TLC again was found to corr

178 Pulmonary function testing showed that O(3)-induced redu

179 Emphysema along the needle path, pulmonary function tests showing ventilatory obstruction

180 Preoperative objective variables (pulmonary function tests, smoking history, demographics,

181 ction (by impedance plethysmography), serial pulmonary function tests (spirometry and diffusion capac

182 e and is variably correlated with results of pulmonary function tests, suggesting that the SF-36 shou

183 When performing infant pulmonary function testing, TAC itself produces a tempor

184 were delivered by C-section and subjected to pulmonary function testing the following day.

185 ment of lung, cardiac, and sleep function by pulmonary function tests, transthoracic echocardiography

186 2.2 to 5.6]) and a mild decrease in certain pulmonary function testing variables, which did not prog

187 A pulmonary function test was performed measuring prebronc

188 Pulmonary function testing was done and in-person interv

189 An obstructive pattern on pulmonary function testing was observed in 57.3% of the

190 Pulmonary function testing was performed according to gu

191 Pulmonary function tests were (%predicted): FEV(1) = 27%

192 ce of lesion from the pleura, and results of pulmonary function tests were analyzed as single and mul

193 Pulmonary function tests were completed on 3,293 subject

194 Pulmonary function tests were done at baseline and at th

195 Serial pulmonary function tests were done.

196 Pulmonary function tests were obtained immediately befor

197 ent a comprehensive clinical assessment, and pulmonary function tests were obtained.

198 tion and expiration, visual HRCT scores, and pulmonary function tests were obtained.

199 Bronchoalveolar lavage and pulmonary function tests were performed at intervals.

200 -terminal pro-brain natriuretic peptide, and pulmonary function tests were performed before (baseline

201 raphy, conventional and thin-section CT, and pulmonary function tests were performed in 39 patients.

202 Serial echocardiograms and pulmonary function tests were performed.

203 functional tests, functional parameters, and pulmonary function tests were secondary outcome measures

204 Pulmonary function tests were similarly obtained before

205 Pulmonary function tests were stable in 22 of the 26 pat

206 Data on cardiopulmonary-exercise and pulmonary-function testing were compared with data obtai

207 ions, computed tomography of lung cysts, and pulmonary-function tests were performed.

208 plete blood count, and serum chemistries and pulmonary function testing with bronchoprovocation in se

209 iagnosing BOS in patients with first drop of pulmonary function tests with a sensitivity of 96% and a

210 Chest X-ray film and pulmonary function tests with diffuse capacity of carbon

211 Pulmonary function tests, X-rays, computed tomographic (